Because SOST and SFRP-1 both act as extracellular antagonists of the Wnt/β-catenin signaling pathway, we suggest that SOST and SFRP-1 play similar roles in patients with DISH. Here, SOST is linked to diffuse idiopathic skeletal hyperostosis.